Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 15,101–15,200 of 15,747
Controlling simulated outbreaks of new SARS-CoV-2 variantsPreprint
Grass, A., Johnson, K. D., Toneian, D., et al. (2021) · arXiv (Cornell University)
A case of COVID-19 vaccination during radiotherapy for breast cancer
Takahashi, N., Takeda, K., Suzuki, Y., et al. (2022) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-022-00134-3
“Vaccine-related adverse events occurred in 21% of the participants who received Tozinameran and in 5% of the participants who received a placebo, and 2 participants who received Tozinameran and 4 participants who received a placebo died [9].”
BackgroundChae, S. H., Park, H., Radnaabaatar, M., Park, H., & Jung, J. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e94
A novel approach to designing viral precision vaccines applied to SARS-CoV-2Preprint
Trabelsi, K., Khalaf, N. B., Ramadan, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3202563/v1
Domingo, J. R. C., Ocampo, A. M. M., Tan‐Lim, C. S. C., Dans, L. F., Dator, M. A., Alejandro, M. A. J. I., Paz, E., Gonzales, M. L. A., & Bagamasbad, P. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5367706
Houy, N., & Flaig, J. (2026) · medRxiv · doi:10.64898/2026.01.19.26344387
Unveiling Fundamentals and Research Opportunities of mRNA Technology
Kumar, D., Singh, A., Kaviraj, S., & Singh, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-0896-3_5
Pericarditis and Myocarditis after mRNA-based COVID-19 Vaccination
Hong, R., Yap, J. J. L., & Yeo, K. K. (2022) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2021.26
Development of drugs and vaccines
Rose, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99149-0.00003-1
Jung, M. (2024) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.24.196 · Cited by 1
Schaffer, A. L., Hulme, W. J., Horne, E. M. F., Parker, E. P. K., Walker, V. M., Stables, C. L., Mehrkar, A., Bacon, S., Bates, C., Goldacre, B. M., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127257 · Cited by 3
“[1,2] However, their benefits wane over time [3] and so booster vaccinations are needed to sustain protection.”
Müller, B., Padberg, I., Lorke, M., Brinks, R., Cripps, S., Gomes, M. G. M., Haake, D., & Ioannidis, J. P. A. (2026) · Scientific Reports · doi:10.1038/s41598-026-36265-z · Cited by 10
Bosch, A. M., Guzman, H. V., & Pérez, R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.15.575706
“7 In this context, the investigation of the interaction of other relevant VoCs with material surfaces has been lagging behind.”
BackgroundGebreyesus, T. D., Shute, T., Alemu, A., Berha, A. B., Maru, M., Gashaw, H., Kifle, M. M., Doherty, J., & Figueras, A. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04145-0
“[ 14, 15 ], and no AESI or seri - ous AEFI were documented.”
Tilch, K., Hopff, S. M., Appel, K. S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3006893/v1
Kute, V. B., Desai, S., Meshram, H. S., Shah, K. N., Chauhan, S., Mishra, V. V., & Sahay, M. (2022) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_7_22
El-Orfali, Y., Mansour, R., Alkalamouni, H., Jabbour, Z. C., Fayad, A. G. A., Saba, E. S., Khawaja, G., & Massaad, M. J. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.10.001 · Cited by 1
Covid Vaccine Risk Stratification
Standaert, L., Munasinghe, T., Jang, D., et al. (2021) · IEEE International Conference on Big Data (BigData) · doi:10.1109/bigdata52589.2021.9671601
Msobo, A., Maphari, P. W., Koorsen, G., Singab, A. N. B., & Mhlongo, M. I. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00620-9 · Cited by 2
“Paxlovid, and Molnupiravir which substantially reduced hospitalisation and mortality rates (Polack et al. 2020; Tang et al. 2022; Extance 2022).”
"Unwinding Our COVID 19 Pandemic Safeguards After Vaccination"
Nahass, R. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.35.005779
“Recent data on 4 vaccines using 2 different platforms suggest that the protection of the vaccine for people getting seriously ill to the point of needing hospitalization or dying is nearly 100%, including variant infections [2-8].”
BackgroundVon Kräutern zu Pillen, Biologics und Nukleinsäuren
Lüscher, T. F., von Eckardstein, A., Beer, J. H., Räber, L., Sudano, I., Nanchen, D., Mueller, C. E., Mach, F., & Landmesser, U. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2022.02258
“Fair Innings,” Women, and Longevity Science
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0008
Zhou, L., Hsieh, C., Leist, S. R., Miller, E. H., Horton, A. P., Shoemaker, S. R., Gardner, E. C., Powers, J. M., Boutz, D. R., Mallory, M. L., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014391 · Cited by 1
Multiorgan Outcomes Following COVID-19 Vaccine vs Infection: 30M AnalysisPreprint
Toraih, E. A., Bruce, D. N., Hussein, M. H., Aiash, H., & Thomas, S. J. (2026) · medRxiv · doi:10.64898/2026.01.30.25343064
Self-citationPope, T., & Johnson, W. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-90509-1.00039-4
mRNA therapy: A novel approach for retinal neurodegenerative diseases
Zhang, B., Tang, J., Zhang, Q., Qiu, Y., Cheng, Y., Yu, S., Liu, L., Xue, J., Liu, X., He, Q., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-01306 · Cited by 3
Wallis, R. S., Srivastava, A. K., Wack, A., & Knirsch, C. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87539-4.00003-8
Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
Murase, K., Takada, K., Arihara, Y., Miyanishi, K., & Kato, J. (2023) · Cureus · doi:10.7759/cureus.41486
“While mRNA COVID-19 vaccination is effective in preventing COVID-19 [5], patients treated with anti-CD20 are unable to mount a meaningful immune response to the vaccine [6-9].”
BackgroundAre Target Trial Emulations the Gold Standard for Observational Studies?: The Authors Respond
Pearce, N. E., & Vandenbroucke, J. P. (2023) · Epidemiology · doi:10.1097/ede.0000000000001668 · Cited by 5
Intracellular protein binders for imaging, control and future therapeutics
Barykina, N. V., & Verkhusha, V. V. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01768-7
Skelly, A. N., Fan, C., Keeffe, J. R., Ökten, A. B., Gavor, E., Newby, M. L., Allen, J. D., Kreider, E. F., Ding, W., Osbaldeston, R. A., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536870123
Влияние вакцинации на исходы COVID-19 у госпитализированных пациентов
Литвинчук, Д. В., Данилов, Д. Е., & Карпов, И. А. (2025) · Клиническая инфектология и паразитология · doi:10.34883/pi.2025.14.2.036
Rahemtoola, M. S., & Pillai, A. (2025) · Cureus · doi:10.7759/cureus.91816
“In fact, trials evaluating Pfizer/BioNTech demonstrated a 95% efficacy at preventing severe COVID-19 [28,29].”
Sood, S., Matar, M. M., Kim, J., Kinsella, M. D., Rayavara, K., Signer, O., Henderson, J., Rogers, J., Chawla, B., Narváez, B., et al. (2023) · bioRxiv · doi:10.1101/2023.08.01.551509 · Cited by 3
Secondary Publication: COVID-19 Pandemic: Drug Development and Treatment
Tsukahara, F., & Maru, Y. (2021) · Institutional Repositories DataBase (IRDB) · doi:10.24488/twmuj.2021004
Traditional Therapies Involving Nutrition for the Management of COVID-19
Ramesh, M., Muthuraman, A., & Anand, K. (2023) · Coronaviruses · doi:10.2174/0126667975250575231018111950
Tholo, N., Markey, G., Harrigan, R., Pandey, P., Prasad, B., Barai, R. S., Gibson, D. S., & Shukla, P. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag260
“The groundbreaking success of messenger ribonucleic acid (mRNA) vaccines illustrated that platform technologies with computational design tools can reduce the timeline to less than a year [ 9].”
Mayer, R. L., Verbeke, R., Asselman, C., Aernout, I., Gul, A., Eggermont, D., Boucher, K. L., Théry, F., Maia, T. M., Demol, H., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.19.504521
Duarte, L. F., Vásquez, Y., Diethelm‐Varela, B., Riedel, C. A., Bueno, S. M., & González, P. A. (2023) · Revista del Instituto de Salud Pública de Chile · doi:10.34052/rispch.v7i1.163
Deep vein thrombosis during vaccination against SARS-CoV-2 period
Alconchel, L. P., Ki, Y. W., González, L. E., Nieto, B. G., Iranzo, N. H., & Álvarez, A. C. M. (2023) · Angiología · doi:10.20960/angiologia.00460
Al‐Darwish, L., Khalayli, N., Almajzoub, R., & Kudsi, M. (2024) · International Journal of Surgery Global Health · doi:10.1097/gh9.0000000000000471
Junghans, R. P. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1994800
Molecular signature of COVID-19 prior to its exacerbation by multi-omics surveyPreprint
Suzuki, T., Kita, Y., Yanagida, K., Maeda, K., Hashidate‐Yoshida, T., Nakanishi, H., Ohto‐Nakanishi, T., Terada-Hirashima, J., Tsujimoto, Y., Hojo, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.27.696524
Ekpenyong, B. N., Mashige, K. P., Osuagwu, U. L., Ishaya, T., Ovenseri-Ogbomo, G. O., Charwe, D. D., Timothy, C. G., Abu, E. K., Oloruntoba, R., Miner, C. A., et al. (2026) · Advances in Public Health · doi:10.1155/adph/6621930
Healy, K., Pin, E., Chen, P., et al. (2021) · medRxiv · doi:10.1101/2021.09.30.21264377
“6% and 95% protection against symptomatic infection and severe disease, respectively, 1-2 weeks after the second dose (2-4).”
Backgroundde Oliveira, J. R. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-24082023-110203
Yan, L., Yi, J., Liu, D., Li, J., Baidoo, A. A. H., & Xie, L. (2025) · Vaccines · doi:10.3390/vaccines13090984
“…have consistently demonstrated the efficacy and safety of vaccines in preventing symptomatic SARS-CoV-2 infection, those trials primarily excluded participants with a documented history of SARS-CoV-2 infection to minimize potential confounding effects on efficacy and safety assessments [3–5].”
COVID-19 Vaccines and their Potential use in Patients with Hematological Malignancies
Dada, A. M., Albishi, G. E., & Usman, B. (2021) · Journal of Applied Hematology · doi:10.4103/joah.joah_28_21
Kreulen, R. T., Margalit, A., Miller, A. S., Srikumaran, U., Wilckens, J. H., & LaPorte, D. M. (2023) · PubMed Central · doi:10.22038/abjs.2023.68418.3263
Vaccination against COVID-19 in Ukraine. Safety of Vaccines
Iakovenko, N. O., Оглобліна, М. В., & Nuzhna, O. K. (2021) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs06.06.200
The challenge of COVID-19 on a teratogen information service in AustraliaPreprint
Baker, M., Fotheringham, P., Kennedy, D. S., & Cupitt, D. (2026) · Research Square · doi:10.21203/rs.3.rs-9992781/v1
Évaluer la balance bénéfices-risques des médicaments: Quelques leçons de la Covid-19
Cracowski, J., Molimard, M., Richard, V. J., Roustit, M., & Khouri, C. (2026) · médecine/sciences · doi:10.1051/medsci/2026040
Recent Advancements in Gene Therapy
Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-7688-3_11
SARS-CoV-2 Immunity following different combinations of vaccination and breakthrough infectionPreprint
Pušnik, J., Monzon-Posadas, W. O., Zorn, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2053251/v1
Niesen, M. J. M., Murugadoss, K., Lenehan, P. J., Marchler‐Bauer, A., Wang, J., Connor, R. P., Brister, J. R., Venkatakrishnan, A., & Soundararajan, V. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac105
Gammazza, A. M., D’Amico, G., Gratie, M. I., Légaré, S., Angileri, F., & Cappello, F. (2026) · Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale · doi:10.4081/jbr.2026.15925
COVID-19 in renal replacement therapy patients: an overview of current data and future challenges
Biedunkiewicz, B., Dębska-Ślizień, A. M., & Tylicki, L. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16336 · Cited by 3
Cardiac effects of drugs and vaccines used to treat and prevent COVID-19
Cubeddu, L. X., & Tailor, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00048-2 · Cited by 1
Evaluation of the United States COVID-19 Vaccine Allocation StrategyPreprint
Islam, M. R., Oraby, T. F., McCombs, A., Chowdhury, M. M., Al-Mamun, M., Tyshenko, M. G., & Kadelka, C. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3869650
COVID-19 and Digestive Diseases: A Comprehensive Review on Pathophysiology and Clinical Management
Ibrahim, N. E., & Hassan, F. M. (2024) · Coronaviruses · doi:10.2174/0126667975293524240625115448
A protocol for computational design of mRNA vaccines with high functionality and specificity
Ramadan, M. A., ElGohary, H. M., Faraag, A. H., & Mysara, M. (2026) · Biology Direct · doi:10.1186/s13062-026-00846-9
Çaykara, B. (2026) · Celal Bayar Üniversitesi Fen Bilimleri Dergisi · doi:10.18466/cbayarfbe.1852257
Rinchai, D., Deola, S., Kabeer, B. S. A., Gentilcore, G., Toufiq, M., Mathew, L. S., Liu, L., Vempalli, F. R., Mubarak, G., Lorenz, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.09.631990
Zhang, Y. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.19728
Rogers, Z. J. (2023) · Digital Repository Service (Northeastern University) · doi:10.17760/d20621546
Advanced lipid nanoparticles for targeted nucleic acid delivery
Deng, Y., Chen, M., Zhou, X., Luo, T., Guo, J., Giles, A., Mourin, T. T., & Chen, G. (2026) · Nano Research · doi:10.26599/nr.2026.94908809
How effective are COVID-19 vaccines? Here’s what the stats mean … and what they don’t
Froda, S., & Larribe, F. (2021) · doi:10.64628/aam.ws6tptmdh
Wong, K., Yuen, B. P., Kwok, C. H. Y., Lin, V. Y. C., Farrington, A. F., Cheung, H. W., Wong, W., & Ho, E. N. M. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70129 · Cited by 1
Roslan, M., Nisfu, F. R. M., Arzmi, M. H., Wahab, R. A., & Zainuddin, N. (2023) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2023.30.4.2 · Cited by 2
Single-cycle SARS-CoV-2 vaccine elicits high protection and sterilizing immunity in hamstersPreprint
Klimkait, T., Lett, M. J., Otte, F., Hauser, D., Schön, J., Kipfer, E. T., Hoffmann, D., Halwe, N. J., Breithaupt, A., Ulrich, L., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3124718/v1
Tavera-Rodríguez, P., Barbosa-Ramírez, J., Bermúdez-Forero, A., Prada-Cardozo, D., Reales-González, J., Peláez‐Carvajal, D., Malo, D., Meneses-Gil, M.-X., & Mercado, M. (2022) · medRxiv · doi:10.1101/2022.05.31.22274501
Suryadinata, N., Christopher, P. M., Michelle, I., Sari, W. R., Cucunawangsih, C., & Lugito, N. P. H. (2023) · PubMed Central · doi:10.21010/ajidv17i2.2 · Cited by 2
COVID-19 Vaccination and Pregnancy
Ignaszak-Kaus, N., Chmaj-Wierzchowska, K., Wszołek, K., & Wilczak, M. (2022) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog4910220 · Cited by 1
Jugniot, N. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119213
CORONAVIRUS (COVID-19) VACCINATION: SCIENTIFIC FACTS. THE GREEK REPORT
Mentis, M. N., Mavroeidi, E., Malevskaia, A., Karalis, N., & Κωνσταντοπούλου, Γ. (2023) · European Journal of Public Health Studies · doi:10.46827/ejphs.v6i2.151
“The vaccine is administered intramuscularly, by injection, and contains a modified nucleoside mRNA (modified RNA) that encodes the protein spike of the SARS-CoV2 virus, making the person's immune system able to recognize the virus and fight it (Polack et al., 2020).”
Kido, K., Ibaragi, K., Tanishima, M., Muramoto, Y., Nakayama, S., Ata, K., Hayashida, K., Nakamura, H., Shinmura, Y., Oda, Y., et al. (2022) · medRxiv · doi:10.1101/2022.10.27.22281603
Lipid nanoparticles as a tool to dissect dendritic cell maturation pathwaysPreprint
Janssens, S., Rennen, S., Bosteels, V., Nolf, C. D., Lil, K. V., Maréchal, S., Vetters, J., Velde, E. V. D., Fayazpour, F., Roelandt, R., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5461735/v1
Harris, R. A., Thirard, R., Baos, S., et al. (2024) · Trials · doi:10.1186/s13063-023-07879-9
“Combinations of different event frequencies (reported in other COVID-19 research [2, 3]), non-inferiority margins, and power were explored to provide a sample size that was both acceptable to the clinical members of the study team and pragmatic given the accelerated time-scale of the trial.”
BackgroundZhang, H., Chen, D., Xue, S., Liu, Z., Yang, X., Zhang, C., Li, D., & Zhang, D. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01272 · Cited by 1
A Systematic Review - Adverse Effect of Covid-19 Vaccine
Kumar, A., Singh, A., & Gupta, B. K. (2025) · Asian Journal of Research in Chemistry · doi:10.52711/0974-4150.2025.00031
Avlasevich, V., & McCarthy, K. J. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231164109
Hussein, N. R., Abdulkareem, W. L., Rasheed, N. A., & Ameen, M. R. (2023) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.17.3.43 · Cited by 1
Matsuyama, A., Mori, T., Ogami, A., Mafune, K., Tateishi, S., Kuwamura, M., Muramatsu, K., Fujino, Y., Mori, K., & the CORoNaWork project (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1290187
“We conducted all analyses using Stata statistical software (release 16; StataCorp LLC, College Station, TX, USA).”
BackgroundMethodSeto, K., Ohashi, Y., Masuda, J., & Terakado, H. (2022) · Global Health & Medicine · doi:10.35772/ghm.2022.01024
Bat-Erdene, O., Miura, K., Maeda, H., Watanabe, S., Tsukui, M., Takaoka, Y., Nomoto, H., Goka, R., Morimoto, N., & Yamamoto, H. (2023) · Gastrointestinal Disorders · doi:10.3390/gidisord5010002
Barrett, E. G., Revelli, D., Bakshi, C. S., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1212179
“As the COVID-19 pandemic progressed, parenterally delivered vaccines have been proven to provide significant protection from symptomatic infection, hospitalization, and death (Polack et al., 2020; Baden et al., 2021).”
BackgroundKashef, A., Fakih, L., Bailey, H., Harling, G., & Jackson, C. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5256836
Antibody testing as the guide to our living with COVID-19
Kaku, N., Nakagama, Y., Nitahara, Y., & Kido, Y. (2022) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.33.338
COVID-19 vaccination in the UK: is it time to celebrate?
Phillis, A. (2021) · British Journal of Community Nursing · doi:10.12968/bjcn.2021.26.2.70
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.